CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.67% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money
7.39
0.4%
Market Trading Hours* (UTC) Open now
Closes on Wednesday at 21:00

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.14
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.024346 %
Charges from full value of position ($-0.24)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
-0.024346%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.002124 %
Charges from full value of position ($0.02)
Trade size with leverage ~ $2,000.00
Money from leverage ~ $1,000.00

Go to platform
0.002124%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 50.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 7.43
Open 7.38
1-Year Change 12.84%
Day's Range 7.17 - 7.48
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 17, 2024 7.43 0.15 2.06% 7.28 7.60 7.11
Dec 16, 2024 7.34 0.17 2.37% 7.17 7.81 6.89
Dec 13, 2024 7.09 -1.08 -13.22% 8.17 8.40 7.02
Dec 12, 2024 8.12 -1.05 -11.45% 9.17 9.17 8.07
Dec 11, 2024 9.20 -0.28 -2.95% 9.48 9.64 9.18
Dec 10, 2024 9.43 -0.59 -5.89% 10.02 10.30 9.21
Dec 9, 2024 10.13 0.11 1.10% 10.02 10.69 10.02
Dec 6, 2024 10.29 0.59 6.08% 9.70 10.33 9.67
Dec 5, 2024 9.44 -0.28 -2.88% 9.72 10.27 9.36
Dec 4, 2024 9.80 -0.62 -5.95% 10.42 10.57 9.67
Dec 3, 2024 10.47 -0.02 -0.19% 10.49 11.42 10.17
Dec 2, 2024 10.72 1.06 10.97% 9.66 10.91 9.63
Nov 29, 2024 10.00 -0.40 -3.85% 10.40 10.47 9.64
Nov 27, 2024 10.38 0.95 10.07% 9.43 10.45 9.24
Nov 26, 2024 9.42 0.24 2.61% 9.18 9.82 8.95
Nov 25, 2024 9.35 0.33 3.66% 9.02 10.02 9.02
Nov 22, 2024 8.85 0.39 4.61% 8.46 9.08 8.34
Nov 21, 2024 8.82 -0.91 -9.35% 9.73 9.73 8.60
Nov 20, 2024 9.72 0.75 8.36% 8.97 9.98 8.87
Nov 19, 2024 9.50 0.50 5.56% 9.00 9.52 8.66

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
Leverage
2:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

IGM Biosciences, Inc. Company profile

About IGM Biosciences Inc

IGM Biosciences, Inc. is a biotechnology company engaged in the development of engineered IgM antibodies for the treatment of multiple diseases. It has developed an IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. Its lead product candidate, IGM-2323, a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, is in an ongoing Phase I clinical trial for the treatment of relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL) patients. Its second product candidate, IGM-8444, is an IgM antibody targeting Death Receptor 5 (DR5) proteins, which is for the treatment of patients with solid and hematologic malignancies. The Company’s pipeline also includes IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.

Financial summary

BRIEF: For the nine months ended 30 September 2021, IGM Biosciences Inc revenues was not reported. Net loss increased from $56.7M to $114.5M. Higher net loss reflects Research and development - Bala increase of 89% to $80.3M (expense), General and administrative - Balanc increase of 67% to $17.1M (expense), Stock-based Compensation in SGA increase from $2.9M to $9.7M (expense).

Industry: Bio Therapeutic Drugs

325 E Middlefield Rd
MOUNTAIN VIEW
CALIFORNIA 94043-4003
US

People also watch

ETH/USD

3,869.41 Price
-1.670% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

BTC/USD

104,210.30 Price
-2.280% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

Gold

2,636.12 Price
-0.410% 1D Chg, %
Long position overnight fee -0.0083%
Short position overnight fee 0.0001%
Overnight fee time 22:00 (UTC)
Spread 0.30

US100

21,988.50 Price
+0.050% 1D Chg, %
Long position overnight fee -0.0243%
Short position overnight fee 0.0021%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 660,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading